Akrevia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Akrevia Therapeutics's estimated annual revenue is currently $17.5M per year.
- Akrevia Therapeutics's estimated revenue per employee is $155,000
- Akrevia Therapeutics's total funding is $233M.
Employee Data
- Akrevia Therapeutics has 113 Employees.
- Akrevia Therapeutics grew their employee count by -18% last year.
Akrevia Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $7M | 45 | 73% | N/A | N/A |
#10 | $5.4M | 35 | 3% | N/A | N/A |
What Is Akrevia Therapeutics?
Akrevia Therapeutics is a biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics. The companyￃﾢ￢ﾂﾬ￢ﾄﾢs proprietary Aklusionￃﾢ￢ﾀﾞￂﾢ platform technology allows biologics to be specifically activated in the tumor microenvironment, and with precisely tailored properties, expanding the universe of natural immune-activating proteins that can be safely delivered. Akrevia is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for patients living with cancer. To learn more, please visit www.akrevia.com. The company is financed by blue chip investors F-Prime Capital Partners and Atlas Venture. Akrevia has licensed key technology from Thomas Jefferson University and City of Hope. The company is located in Cambridge, Massachusetts.
keywords:N/A
$233M
Total Funding
113
Number of Employees
$17.5M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Akrevia Therapeutics News
Akrevia Therapeutic, a Cambridge, MA-based biotech startup focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics has raised $30 million in funding led by F-Prime Capital Partners and Atlas Venture. The funding will be used to accelerate Akrevia’s pipeline and proprieta ...
Akrevia Therapeutics, a Cambridge, Mass.-based biopharmaceutical company focused on developing tumor-targeted immuno-oncology therapeutics, closed a $30m Series A financing. The round was led by F-Prime Capital Partners and Atlas Venture. The company intends to use the funds to accelerate the ...
Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced the closing of a $30 million Series A financing led by F-Prime Capital Partners and Atlas Venture. The investors have come together t ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 113 | 16% | N/A |
#2 | $17.5M | 113 | 23% | N/A |
#3 | $11.3M | 113 | 4% | N/A |
#4 | $20.5M | 114 | -1% | N/A |
#5 | $20.5M | 114 | 48% | N/A |